Table 1.
Comparison of the clinicopathological manifestations between IgAN-NS and IgAN-NR.
| IgAN-NR | IgAN-NS | p | |
|---|---|---|---|
| N | 111 | 111 | |
| Age, y | 41.00 [33.50, 50.00] | 41.00 [27.00, 54.00] | .7 |
| Male | 63 (56.8) | 55 (49.5) | .3 |
| Follow-up duration,m | 39.53 [17.95, 67.58] | 36.50 [13.98, 72.27] | .5 |
| eGFR | 61.49 (29.46) | 61.68 (37.37) | .9 |
| Body mass index | 30.62 (40.21) | 23.74 (36.65) | .1 |
| Systolic blood pressure, mmHg | 128.90 (13.68) | 129.11 (14.28) | .9 |
| Diastolic blood pressure, mmHg | 80.15 (8.21) | 78.98 (11.48) | .4 |
| Mean arterial pressure, mmHg | 123.11 (11.79) | 122.02 (14.58) | .6 |
| Hemoglobin, g/L | 126.67 (21.06) | 113.49 (23.16) | <.001 |
| Serum creatinine, mg/dL | 1.96 (2.20) | 2.21 (2.60) | .4 |
| Serum albumin, g/L | 35.74 (4.58) | 24.95 (3.96) | <.001 |
| Total cholesterol, mmol/L | 5.75 (1.60) | 6.91 (2.42) | <.001 |
| Triglyceride, mmol/L | 2.93 (2.15) | 2.26 (1.26) | .005 |
| HDL-cholesterol, mmol/L | 1.06 (0.27) | 1.21 (0.53) | .01 |
| LDL-cholesterol, mmol/L | 3.14 (1.06) | 4.13 (1.57) | <.001 |
| Uric acid, mmol/L | 420.76 (97.55) | 409.30 (127.72) | .5 |
| Fibrinogen, g/L | 4.34 (1.05) | 4.79 (1.40) | .008 |
| C-reactive protein, g/L | 4.10 (5.33) | 10.77 (24.89) | .006 |
| Serum IgA, g/L | 3.48 (1.22) | 3.22 (1.33) | .1 |
| Proteinuria, g/24 h | 5.66 (2.29) | 7.35 (3.17) | <.001 |
| Urine red blood cell count, RBC/μL | 157.49 [43.26, 499.54] | 297.90 [94.48, 836.96] | .04 |
| Urine white blood cell count, WBC/μL | 125.50 [65.41, 261.33] | 202.56 [107.36, 467.60] | .002 |
| Composite endpoint | 34 (30.6) | 38 (34.2) | .7 |
| CR | 49 (44.1) | 54 (48.6) | .7 |
| PR | 39 (35.1) | 39 (35.1) | 1 |
| Therapy | |||
| Renin-angiotensinsystem inhibito | 100 (90.1) | 94 (84.7) | .3 |
| Steroid | 74 (66.7) | 96 (86.5) | .001 |
| Immunosuppressant | 57 (51.4) | 48 (43.2) | .3 |
| Renal biopsy | |||
| Number of glomeruli | 19.58 (10.61) | 20.81 (10.28) | .4 |
| Proportion of glomerulosclerosis, % | 39.91 (27.32 | 32.52 (23.43) | .04 |
| Oxford classification | |||
| M1 | 27 (40.3) | 46 (59.0) | .04 |
| E1 | 37 (51.4) | 48 (59.3) | .4 |
| S1 | 56 (80.0) | 62 (77.5) | .9 |
| T | .3 | ||
| T1 | 25 (34.7) | 20 (24.7) | |
| T2 | 25 (34.7) | 28 (34.6) | |
| C1 | 68 (61.3) | 68 (61.3) | 1 |
| Immunofluorescence | |||
| IgA | .7 | ||
| + | 40 (36.0) | 36 (32.4) | |
| ++ | 8 (7.2) | 13 (11.7) | |
| +++ | 62 (55.9) | 61 (55.0) | |
| ++++ | 1 (0.9) | 1 (0.9) | |
| IgM | .9 | ||
| + | 34 (30.6) | 30 (27.0) | |
| ++ | 12 (10.8) | 14 (12.6) | |
| +++ | 1 (0.9) | 2 (1.8) | |
| IgG | .7 | ||
| + | 7 (6.3) | 7 (6.3) | |
| ++ | 5 (4.5) | 2 (1.8) | |
| +++ | 1 (0.9) | 1 (0.9) | |
| C3 | .3 | ||
| + | 42 (37.8) | 36 (32.4) | |
| ++ | 36 (32.4) | 28 (25.2) | |
| +++ | 24 (21.6) | 34 (30.6) | |
| C4 | 1 | ||
| ++++ | 1 (0.9) | 0 (0.0) |
Numerical variables are reported as means (SD) or medians [IQR], while categorical variables are presented as counts (%). The composite endpoint was referred to a continuous decline in estimated eGFR from baseline of ≥30% or reaching ESRD.
IgAN-NS refers to IgAN with NS, while IgAN-NR represents IgAN with nephrotic-range proteinuria. E1 signifies endocapillary hypercellularity, M1 denotes mesangial hypercellularity, T1-2 refers to the severity of interstitial fibrosis/tubular atrophy, and S1 indicates segmental glomerulosclerosis/adhesion. C1 indicates the presence of crescent. CR signifies complete remission of proteinuria, while PR denotes partial remission of proteinuria.
P-value was adjusted for multiple comparisons.